Weight loss drug megatrend: $73-87B market, LLY/NVO leaders
GLP-1 / Obesity Revolution
| Symbol | Action | Vol | Stop Loss | Take Profit | Size | Links |
|---|---|---|---|---|---|---|
| PFE | BUY | 25% | 18.6% below entry | 5.3% above entry | 5.4% | TVYH |
| PLNT | BUY | 31% | 23.8% below entry | 6.8% above entry | 4.2% | TVYH |
| ISRG | BUY | 32% | 24.3% below entry | 6.9% above entry | 4.1% | TVYH |
| AMGN | BUY | 27% | 20.2% below entry | 5.8% above entry | 4.9% | TVYH |
| LLY | BUY | 38% | 28.9% below entry | 8.3% above entry | 3.4% | TVYH |
| MRK | BUY | 27% | 20.7% below entry | 5.9% above entry | 4.8% | TVYH |
| ABBV | BUY | 26% | 20.0% below entry | 5.7% above entry | 5.0% | TVYH |
| VKTX | BUY | 81% | 40.0% below entry | 15.5% above entry | 1.8% | TVYH |
This strategy has moderate long-term potential but requires monitoring. - Take profit: Rebalance when any position exceeds 2x its target weight. Trim back to target, redeploy to underweight positions. - Stop loss: NO price-based stop loss. This strategy recovered from -25% drawdown to return 125% long-term. - Exit rule: Review annually. Exit if strategy underperforms its benchmark for 3 consecutive years.